Logo
Company Profile

CurifyLabs Oy

CurifyLabs Oy: Advancements in Personalized Medicine Through EIC Accelerator Funding

FinlandEIC Accelerator2023

Table of Contents

  1. The EIC Accelerator Project
  2. The Funding Rounds
  3. The Press Releases
  4. The Technology Advancements
  5. The Partnerships and Customers
  6. The Hiring and Company Growth
  7. The Media Features and Publications

1 The EIC Accelerator Project

The EIC Accelerator Program

The European Innovation Council (EIC) Accelerator program is a key component of the EIC, designed to support innovative startups and small-to-medium enterprises (SMEs) aiming to develop and scale breakthrough technologies. Specifically tailored for European deep-tech companies, this program addresses the critical gap in financing that many innovative ventures face, particularly in their early stages. The EIC Accelerator provides a combination of grant funding and equity investment, thereby catering to the diverse needs of startups in their growth journey.

Funding Structure

The EIC Accelerator offers a unique funding model that consists of two main components:

1. Grant Funding: Startups can receive grants of up to €2.5 million. This non-repayable funding is aimed at covering the costs associated with the development and validation of innovative projects. The grant serves as a financial cushion, allowing companies to focus on research and development without the immediate pressure of generating revenue.
2. Equity Investment: In addition to grants, the EIC Accelerator provides equity funding, which has evolved over time. Until the end of 2024, the program offers equity investment of up to €15 million. From 2025 onwards, this equity support will be capped at €10 million. This equity investment not only provides essential capital but also signals to private investors the viability of the startup, thereby attracting additional funding to help scale operations.

This dual funding structure empowers startups to pursue ambitious projects, develop innovative solutions, and ultimately scale their businesses in competitive markets.

Purpose and Role in the Ecosystem

The EIC Accelerator plays a pivotal role in the European deep-tech and startup ecosystem. It aims to foster innovation by providing financial support to high-risk, high-reward projects. The program encourages the commercialization of cutting-edge technologies that address societal challenges, thereby contributing to economic growth and job creation in Europe.

By offering both grant funding and equity investment, the EIC Accelerator helps startups bridge the funding gap that often exists between early-stage development and market entry. The program not only supports the financial needs of these companies but also enhances their credibility in the eyes of private investors. As a result, EIC Accelerator-backed companies are better positioned to secure additional funding from venture capitalists and other private sector sources.

CurifyLabs Oy and the PMed Project

Company Overview: CurifyLabs Oy, a Finnish startup, is a trailblazer in the field of personalized medicine. The company focuses on leveraging advanced technologies, particularly 3D printing, to revolutionize the way medications are delivered to patients.

Project Overview (PMed): The PMed project, funded through the EIC Accelerator, aims to enable the production of patient-specific medicines using 3D printing technology in hospitals and pharmacies. This innovative approach allows for the customization of drug dosages and formulations tailored to individual patient needs, thereby improving therapeutic outcomes and minimizing adverse effects.

Technology Background

The technology underlying the PMed project is rooted in the principles of additive manufacturing, commonly known as 3D printing. This process involves creating three-dimensional objects layer by layer from digital models. In the context of pharmaceuticals, 3D printing allows for the precise control of drug formulation, enabling the production of solid dosage forms such as tablets and capsules that can be tailored to specific patient profiles.

1. Customization: One of the key advantages of 3D printing in medicine is the ability to customize dosages and drug combinations. Patients with varying needs can receive medications that are specifically designed for their unique health conditions, thereby enhancing treatment efficacy.
2. Rapid Prototyping: 3D printing facilitates the rapid prototyping of new drug formulations. This can significantly accelerate the development process, allowing for quicker adjustments based on clinical feedback.
3. Cost Efficiency: By enabling on-site production in hospitals and pharmacies, 3D printing can reduce the costs associated with traditional drug manufacturing and supply chain logistics. This is particularly beneficial for rare diseases or conditions requiring specialized treatments.
4. Regulatory Considerations: While 3D printing holds significant promise, it also presents regulatory challenges. CurifyLabs Oy is committed to navigating these complexities to ensure that their 3D-printed medicines meet all safety and efficacy standards.

The PMed project is a testament to the potential of combining innovative technology with healthcare solutions. By securing funding through the EIC Accelerator, CurifyLabs Oy is poised to make significant advancements in personalized medicine, ultimately leading to better health outcomes and improved patient care across Europe.

In conclusion, the EIC Accelerator program not only provides vital funding support to innovative startups like CurifyLabs Oy but also plays a crucial role in transforming the European deep-tech landscape, fostering an environment where groundbreaking ideas can thrive and make a meaningful impact.

2 The Funding Rounds

CurifyLabs Oy: Financing and Funding Event Overview Since EIC Accelerator Award

CurifyLabs Oy, a Finnish medtech startup founded in 2021, has been notably active on the funding front since being selected as an EIC Accelerator winner in January 2023.

Financing Raised

  • EIC Accelerator Grant: In early 2023, CurifyLabs was awarded a €2.5 million non-dilutive grant from the European Innovation Council (EIC) Accelerator program. This significant funding is aimed at advancing their MiniLab solution for personalized medicine compounding.
  • Business Finland Deep Tech Accelerator: The company also received support from Business Finland’s Deep Tech Accelerator program. This comprises two phases:
  • Phase one: €400,000 grant
  • Phase two: Up to €1 million loan
The first phase grant has already been confirmed and supports scaling operations and research commercialization.

Funding Rounds and Timing

  • April 2023: Public announcement of the €2.5 million EIC grant was made around April 2023 following their successful application in January's cut-off round.
  • Late 2022–Early 2023: Business Finland’s deep tech accelerator support was awarded during this period with official news releases published soon after.
  • No evidence exists of additional large-scale equity rounds or priced venture rounds since early-stage investments.

Investor Information

CurifyLabs is backed by a blend of institutional and venture investors: - Lifeline Ventures – An established early-stage VC firm specializing in high-growth Finnish startups.

  • Pharmacy Pension Fund (Apteekkien Eläkesäätiö) – A significant institutional investor active in healthcare sector innovation.
    • These investors have provided capital alongside public grants to enable CurifyLabs’ rapid development and market entry.

    Further Details on Funding Rounds

    While detailed breakdowns (such as seed or Series A/B/C terminology) are not publicly disclosed for specific private rounds post-EIC win, Dealroom estimates indicate that earlier fundraising included small VC-type investments but did not disclose exact amounts beyond non-dilutive grants after January 2023; total enterprise valuation estimated between $9–13 million as of April 2022. There is no public record of major new equity or convertible investment rounds following the EIC award.

    Company Valuations

    The most recent available enterprise valuation estimate placed CurifyLabs between $9–13 million USD as of April 2022—prior to securing several substantial grants. The influx of non-dilutive financing likely enhanced this figure but updated market valuations have not been publicly announced since then.

    Exit Events (IPO/Buyouts/Acquisitions)

    As of May 2025:

  • There are no reports or announcements regarding any IPO process, buyout offers, or acquisition events involving CurifyLabs.

    • The company remains privately held with backing from its original venture investors alongside significant European public innovation funds.

    Sources

    3 The Press Releases

    CurifyLabs Oy: A Finnish Pioneer in Personalized Medicine

    Overview

    CurifyLabs Oy, a Finnish med-tech company based in Helsinki, has been making significant strides in the pharmaceutical industry, particularly in personalized medicine. Founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius, CurifyLabs focuses on automating drug compounding processes to enhance patient safety and treatment efficacy.

    EIC Accelerator Funding

    On January 11, 2023, CurifyLabs was awarded €2.5 million from the European Innovation Council (EIC) Accelerator program. This prestigious grant supports the development of their innovative MiniLab technology, designed to enable hospitals and pharmacies to produce customized medicines using 3D printing. This technology aims to streamline the drug compounding process, making personalized treatments more accessible and safer for patients.

    MiniLab Technology

    The MiniLab is a proprietary manufacturing solution that leverages cutting-edge technology to revolutionize the drug compounding process. It allows for the tailored 3D printing of bespoke pharmaceuticals by compounding pharmacies, reducing manual labor and improving the quality control of personalized medicines. This solution is particularly focused on meeting the needs in pediatrics and oncology, where standard dosing often leads to poor treatment efficacy and undesirable side effects.

    Pilot Programs and Expansion

    CurifyLabs' MiniLab technology has already been successfully piloted by several pharmacies across Europe, including Finland, Spain, Switzerland, Germany, and the Netherlands. The EIC funding will further accelerate the development and scaling of this technology, enabling CurifyLabs to standardize drug formulations and quality control solutions for broader therapeutic applications.

    Impact and Future Plans

    The funding from the EIC Accelerator will be instrumental in advancing CurifyLabs' mission to provide high-quality, personalized medicines across Europe. Charlotta Topelius, CEO of CurifyLabs, highlighted the significance of this grant in bringing a game-changing 3D printing solution to European pharmacists, addressing the growing demand for personalized therapies.

    Press Releases and Updates

    While specific press releases on CurifyLabs' website or social media are not detailed, the company's achievement in securing EIC funding has been widely reported in media outlets, reflecting its innovative approach to pharmaceutical manufacturing.

    Sources

    4 The Technology Advancements

    Current Capabilities of CurifyLabs Oy from Finland

    CurifyLabs Oy, a Finnish health technology company, specializes in developing solutions for manufacturing personalized medicines. Their technology enhances medication safety while reducing costs, particularly through automated non-sterile pharmacy compounding solutions.

    Advancements Since EIC Accelerator Funding

    Since receiving the EIC Accelerator funding in early 2023, CurifyLabs has made significant advancements:

    • Partnership with APL: CurifyLabs partnered with APL, a leading Swedish manufacturer of extemporaneous medicines, to leverage 3D printing technology for creating personalized medicines. This collaboration aims to improve medicine administration for critically ill patients and children by offering precise dosing and flexible dosage forms.
    • Acquisition of Mehta Heino's Intellectual Property: CurifyLabs acquired significant intellectual property from Mehta Heino Industries Oy, enhancing its 3D printing capabilities for personalized medicine production. This acquisition includes Petri Heino joining CurifyLabs as Lead Hardware Engineer, further bolstering the company's expertise.
    • Funding from Business Finland: Besides the EIC funding, CurifyLabs received Deep Tech Accelerator funding from Business Finland. This grant includes EUR 400,000 for the first phase, with a potential loan of EUR 1 million in the second phase, supporting research-driven development.

    Technology Improvements and Demonstrations

    CurifyLabs' technology has seen substantial improvements:

    • MiniLab Technology: The company's MiniLab solution is a smart drug formulation platform that incorporates cutting-edge technology to redefine the drug compounding process. This technology has been successfully piloted in several European countries, including Finland, Spain, Switzerland, Germany, and the Netherlands.
    • Semi-Solid Extrusion (SSE) for Pediatric Care: CurifyLabs' Automated Compounding System (ACS), powered by SSE, has shown groundbreaking potential in pediatric care by ensuring consistent quality and precision in medication production. This innovation addresses the variability often associated with manual compounding.

    Patents, Studies, and Clinical Trials

    While specific patent filings or new scientific studies directly linked to the EIC funding are not detailed, CurifyLabs' advancements in 3D printing and personalized medicine manufacturing have been showcased through partnerships and technology enhancements.

    Market Demonstrations

    CurifyLabs is actively demonstrating its technology in the market through various events and partnerships:

  • World Tour 2025: The company is conducting a global tour to showcase its digital compounding solutions at prominent industry events, including the EAHP Congress and APhA 2025.

    • Sources

    • CurifyLabs World Tour 2025 - News
    • CurifyLabs
    • APL and CurifyLabs Partnership to Support Critically Ill Patients with 3D Printing Medicine Technology
    • APL and CurifyLabs Partner to Support Patients with 3D Printing Medicine Technology
    • CurifyLabs Acquires Intellectual Property from Mehta Heino
    • Finnish Medtech CurifyLabs Secures €2.5M from EIC
    • Evaluation of CurifyLabs Technology in the European Journal of Pharmaceutical Sciences
    • APL and CurifyLabs Use 3D Printing for Medicine Administration

    • 5 The Partnerships and Customers

      CurifyLabs Oy: Partnerships and Market Positioning Since EIC Accelerator Funding

      CurifyLabs Oy, a Finnish company, received the EIC Accelerator funding on January 11, 2023. Since then, the company has made significant strides in partnerships and technology advancements, further solidifying its position in the global market.

      Partnerships and Customers

      CurifyLabs has partnered with several notable entities:

      • The Woodlands Compounding Pharmacy: Located in Houston, Texas, this partnership highlights CurifyLabs' ability to automate compounded medicines, enhancing production efficiency and quality. The collaboration has been successful, with positive feedback from the pharmacy staff, indicating the innovative impact of CurifyLabs' technology on pharmacy operations.
      • APL: In a partnership aimed at supporting critically ill patients, CurifyLabs and APL are utilizing 3D printing medicine technology. This collaboration underscores CurifyLabs' commitment to advancing personalized medicine through innovative technologies.
      • Prinses Máxima Center: This Dutch hospital is implementing CurifyLabs' compounding technology to advance personalized pediatric treatments. The partnership demonstrates CurifyLabs' influence in adapting medications for children, ensuring precise dosing and improving treatment outcomes.

      New Partners and Customers

      As of the latest updates, CurifyLabs has continued to expand its network by securing major contracts with prominent customers and exploring new partnerships:

      • New Partnerships: While specific names of new partners are not detailed in recent announcements, CurifyLabs is focused on deepening partnerships with entities that share its vision of transforming personalized medicine.
      • New Customers: The company has secured major contracts with prominent customers but has not specifically named them in recent updates.

      Nature of New Relationships

      These partnerships and customer relationships are centered around advancing personalized medicine through innovative technologies like 3D printing and automation. They are designed to enhance the production quality and efficiency of customized medications, positioning CurifyLabs as a leader in this field.

      Positioning in the Market

      CurifyLabs' partnerships and customer relationships have significantly enhanced its market position. By collaborating with both U.S.-based pharmacies and European institutions, CurifyLabs demonstrates its global reach and commitment to personalized healthcare. These relationships help CurifyLabs scale its operations, innovate further, and solidify its influence in the pharmacy technology sector.

      Technology Advancements and Scaling

      The partnerships have facilitated technology advancements by enabling CurifyLabs to apply its innovative solutions in real-world settings. For instance, the partnership with The Woodlands Compounding Pharmacy showcases the practical application of CurifyLabs' automation technology, while the collaboration with APL and Prinses Máxima Center underscores its capabilities in 3D printing medicine. This not only enhances CurifyLabs' technological capabilities but also aids in scaling its commercial operations by expanding its market presence and deepening partnerships with like-minded entities.

      Sources:

      6 The Hiring and Company Growth

      CurifyLabs Oy: Growth and Developments

      CurifyLabs Oy, a Finnish company specializing in automated compounding systems for personalized medicine, received the EIC Accelerator funding on January 11, 2023. Since then, the company has been on a significant growth trajectory, focusing on expanding its innovative solutions globally.

      Hiring and Team Growth

      Current Headcount and Team Size: Unfortunately, specific details about CurifyLabs Oy's current headcount or team size are not available in the public domain. However, the company is part of the Health Incubator Helsinki, which provides support for startups to grow their teams and operations.

      Hiring Status: While there are no explicit announcements about current hiring, CurifyLabs' involvement in various events and its growth trajectory suggest ongoing recruitment efforts to support its expansion plans.

      Growth and Scale

      Growth Rate: Since receiving the EIC funding, CurifyLabs has been actively engaged in international events and conferences, showcasing its cutting-edge compounding systems. This increased visibility highlights the company's rapid growth in the healthcare technology sector.

      Key Positions and Recent Hires: Specific information about recent hires is not available. However, the company's focus on innovation in personalized medicine suggests that any new team members would be crucial in advancing its technological capabilities and expanding its market presence.

      Impact of New Team Members

      New team members at CurifyLabs would play a pivotal role in driving the company's vision for transforming healthcare through automation and precision medication. Their contributions would be essential in scaling the business, enhancing product development, and fostering strong relationships with global partners and customers.

      Management and Founding Team Changes

      There are no reported major changes in the management or founding team at CurifyLabs Oy since the EIC funding. The company continues to be supported by Lifeline Ventures, with Juha Lindfors involved as a key partner, indicating a stable strategic direction.

      Future Prospects

      CurifyLabs' future growth is heavily influenced by its innovative approach to personalized medicine. By leveraging automation and digital technologies, the company aims to address global challenges related to medication suitability and availability. Its participation in funding platforms like Springvest further underscores its commitment to scaling and developing its solutions.

      Sources:

      7 The Media Features and Publications

      CurifyLabs Oy, the Finnish healthtech company awarded €2.5 million from the European Innovation Council (EIC) Accelerator in 2023, has expanded its global footprint through strategic media engagements, partnerships, and event participation. Below is a detailed overview of their activities since receiving the grant:

      Media Features & Publications

      • MTV Uutiset (Finland) covered CurifyLabs’ CSS technology for manufacturing personalized medicines during pandemics and drug shortagesnews.curifylabs.com.
      • Taloussanomat, Finland’s largest business daily, highlighted their automated compounding solutions for pharmacies and growth trajectory post-launchnews.curifylabs.com.
      • Tech.eu reported on their acquisition of 3D printing IP from Mehta Heino Industries Oy to enhance personalized medicine productiontech.eu.
      • VoxelMatters featured their GMP-compliant Pharma Inks for scalable 3D printing of bespoke medicationsvoxelmatters.com.

      Podcasts & Interviews

    • The Nordic Venture Show podcast dedicated an episode to CurifyLabs’ innovation in automating pharmacy compounding and global scaling strategiesnews.curifylabs.com.

      • Conference & Event Participation

      1. #PediatRxCon34 (April 9–12, 2025) focused on pediatric pharmaceutical advancementsnews.curifylabs.com.
      2. APhA2025 (Nashville) included presentations on their compounding technologies for pharmacists.
      3. EAHP Congress 2025, where post-event thanks emphasized collaborative efforts in hospital pharmacy innovation.

      Recent Collaborations & Milestones

    • Partnership with Germany’s Helios hospitals involved deploying Pharmaprinter devices at Johannes Wesling Klinikum Minden, showcased by WDR television

      Sources:

      • [Curifying Medicines: MTV News Feature](https://news.curifylabs.com/curified-on-tv" class="inline-link" target="_blank" rel="noopener noreferrer">news.curifylabs.com
      • Automating Pharmacy Compounding - Taloussanomat Report Note: Original Taloussanomat link unavailable; provided alternative context
      • GMP Pharma Inks Launch - VoxelMatters Coverage Example placeholder replaced; actual source: Curifying Pharma Inks Report
      • [Nordic Venture Podcast Episode Detail Page at Curified Newsroom]() Original podcast link not directly cited; company newsroom provides reference
      • [#PediatRxCon34 Participation Announcement via Blog Author Page Filter]() Date-specific links unavailable due to pagination limitations.

    Do you need EIC Accelerator support?

    Here is a list of the key service options for the EIC Accelerator:

    Full Writing Service

    All proposal sections are written by Stephan Segler, PhD.

    Segler Consulting: Full Writing

    Advisory Service

    You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.

    Rasph: Advisory Support

    AI Writer & Training

    A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.

    ChatEIC: AI WriterChatEIC: Training & Reviews

    EIC Accelerator Winner - 2023

    EIC Accelerator Deadline

    00
    Days
    00
    Hours
    00
    Minutes
    00
    Seconds

    How Can We Help You Succeed?

    AI Writer

    Budget-friendly AI tools, templates and instructions

    Advisory Service

    Personalized support for teams with in-house writers

    Full Writing

    Full Writing of all Proposal Sections by Stephan Segler, PhD